Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101

Article  CAS  PubMed  Google Scholar 

Vogelius IR, Bentzen SM (2020) Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 107(2):299–304

Article  PubMed  PubMed Central  Google Scholar 

Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60(4):1013–1015

Article  PubMed  Google Scholar 

Tucker SL et al (2011) Estimation of alpha/beta for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 81(2):600–605

Article  PubMed  PubMed Central  Google Scholar 

Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060

Article  PubMed  PubMed Central  Google Scholar 

Catton CN et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1884–1890

Article  CAS  PubMed  Google Scholar 

Lee WR et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325–2332

Article  PubMed  PubMed Central  Google Scholar 

Morgan SC et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol 36(34):JCO1801097

Article  PubMed  Google Scholar 

Widmark A et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385–395

Article  PubMed  Google Scholar 

Fransson P et al (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22(2):235–245

Article  PubMed  Google Scholar 

Madsen BL et al (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67(4):1099

Article  PubMed  Google Scholar 

King CR et al (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82(2):877–882

Article  PubMed  Google Scholar 

Katz A, Formenti SC, Kang J (2016) Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: risk-stratification and patterns of failure. Front Oncol 6:168

Article  PubMed  PubMed Central  Google Scholar 

Musunuru HB et al (2016) Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol 118(1):112–117

Article  PubMed  Google Scholar 

Alayed Y et al (2018) Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials. Radiother Oncol 127(2):213–218

Article  PubMed  Google Scholar 

McBride SM et al (2012) Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118(15):3681–3690

Article  PubMed  Google Scholar 

Mantz C (2014) A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol 4:279

Article  PubMed  PubMed Central  Google Scholar 

Meier RM et al (2018) Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys 102(2):296–303

Article  PubMed  Google Scholar 

Kataria S et al (2017) Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: an ablative procedure? Front Oncol 7:157

Article  PubMed  PubMed Central  Google Scholar 

Alayed Y et al (2020) Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol 149:8–13

Article  CAS  PubMed  Google Scholar 

Kishan AU et al (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the mirage randomized clinical trial. JAMA Oncol 9(3):365–373

Article  PubMed  PubMed Central  Google Scholar 

Kishan AU et al (2019) Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open 2(2):e188006

Article  PubMed  PubMed Central  Google Scholar 

Brand DH et al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531–1543

Article  PubMed  PubMed Central  Google Scholar 

Tree AC et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23(10):1308–1320

Article  PubMed  Google Scholar 

Fuller DB et al (2018) Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes. Eur Urol Oncol 1(6):540–547

Article  PubMed  Google Scholar 

Aluwini S et al (2013) Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 8:84

Article  PubMed  PubMed Central  Google Scholar 

Jabbari S et al (2012) Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82(1):228–234

Article  PubMed  Google Scholar 

Pontoriero A et al (2016) High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: preliminary results in 26 patients. Technol Cancer Res Treat 15(1):179–185

Article  CAS  PubMed  Google Scholar 

Kawakami S et al (2022) A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer. Radiat Oncol 17(1):67

Article  CAS  PubMed  PubMed Central  Google Scholar 

Magli A et al (2021) Toxicity at 1 year after stereotactic body radiation therapy in 3 fractions for localized prostate cancer. Int J Radiat Oncol Biol Phys 111(1):93–100

Article  PubMed  Google Scholar 

Alayed Y et al (2019) Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial. Radiother Oncol 135:86–90

Article  PubMed  Google Scholar 

Ong WL et al (2023) Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion—results from the 2SMART phase 2 trial. Radiother Oncol 181:109503

Article  PubMed  Google Scholar 

Nicolae A et al (2015) Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated stereotactic ablative body radiotherapy (SABR). Radiat Oncol 10:122

Article  PubMed  PubMed Central  Google Scholar 

Ong WL et al (2023) To boost or not to boost: pooled analyses from 2-fraction SABR trials for localized prostate cancer. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2023.06.250

Article  PubMed  Google Scholar 

Alayed Y et al (2019) Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: a quality of life analysis of two prospective clinical trials. Radiother Oncol 140:105–109

Article  PubMed  Google Scholar 

Greco C et al (2021) Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT Phase 2 randomized clinical trial. JAMA Oncol 7(5):700–708

Article  PubMed  Google Scholar 

Zilli T et al (2019) Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiother Oncol 139:83–86

Article  PubMed  Google Scholar 

King MT et al (2021) Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement. Brachytherapy 20(6):1114–1129

Article  PubMed  Google Scholar 

Annede P et al (2020) Radiobiology: foundation and new insights in modeling brachytherapy effects. Semin Radiat Oncol 30(1):4–15